Skip to main content
OpenTrials
Completed

NCT Number: NCT00274560

A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.

The objective of the study was to evaluate the degree of improvement in lung function in patients with chronic obstructive pulmonary disease (COPD) after treatment with tiotropium inhalation capsules compared to salmeterol inhalation aerosol .

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

HEMO Oy Health Center, Lahti, Finland

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to sign a written Informed Consent Form consistent with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial (i.e., prior to any study procedures, including any pre-study washout of medications).
  • Age of 40 years or older.
  • Smoking history of ≥10 pack-years.
  • A diagnosis of relatively stable chronic obstructive pulmonary disease with an Forced expiratory volume in one second (FEV1) ≤60% of predicted normal and FEV1 ≤70% of Forced vital capacity (FVC).
  • Ability to perform technically acceptable pulmonary function tests, and ability to maintain records during the study period as required in the protocol.
  • Ability to inhale medication from the HandiHaler® and from a metered dose inhaler.

Exclusion criteria

  • Clinically significant diseases other than Chronic obstructive pulmonary disease (COPD). A clinically significant disease was defined as a disease or condition which, in the opinion of the investigator, could have put the patient at risk because of participation in the study or may have influenced either the results of the study or the patient's ability to participate in the study.
  • Known moderate or severe renal insufficiency.
  • A recent history (i.e., six months or less) of myocardial infarction.
  • Unstable or life-threatening cardiac arrhythmias, including newly diagnosed, clinically relevant arrhythmia on the electrocardiogram (ECG) performed on Visit 1. Unstable arrhythmias included arrhythmias that required an intervention (i.e., hospitalization, cardioversion, pacemaker placement, and automatic implantable cardiac defibrillator (AICD) placement) or a change in drug therapy during the year preceding study enrollment.
  • Hospitalization for heart failure during the past three years.
  • History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis.
  • Other exclusion criteria apply.

Treatment and study plan

Tiotropium

Drug

Salmeterol

Drug

Primary outcomes

  1. FEV1 area under the curve for the time period of 0 to 12 hours (FEV1 AUC0-12)

    Time frame: 12 weeks

  2. peak FEV1

    Time frame: 12 weeks

Secondary outcomes

  1. Trough FEV1: Trough FEV1 was the FEV1 measured prior to dosing

    Time frame: 12 weeks

  2. Trough and peak FVC and FVC AUC0-12 measured at the same times as FEV1 on each test day

    Time frame: 12 weeks

  3. Individual FEV1 and FVC measurements at each timepoint

    Time frame: 12 weeks

  4. Number (%) of patients with at least one exacerbation of COPD

    Time frame: 12 weeks

  5. time to first exacerbation

    Time frame: 12 weeks

  6. number of exacerbations

    Time frame: 12 weeks

  7. number of exacerbation days

    Time frame: 12 weeks

  8. Average daily occasions of rescue medication [albuterol (salbutamol)] use each week

    Time frame: 12 weeks

  9. All adverse events

    Time frame: 12 weeks

  10. Pulse rate measured in conjunction with spirometry

    Time frame: 12 weeks

  11. Blood pressure (seated) measured in conjunction with spirometry

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol in a 12 Week, Randomized, Double-Blind, Double-Dummy Parallel Group Study in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Important dates

Study start
2002
Primary completion
2003
First posted
Jan 11, 2006
Registry last updated
Dec 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.